BioDelivery Sciences Intl, Inc. Wrrt
BDSIW
NASDAQ0.04
USD
-0.01
- -
CIK
0001103021
ISIN
US0742411046
Return %
Stock
S&P500
1Y
- -
18.21
3Y
- -
64.38
5Y
- -
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 4131 ParkLake Avenue, Suite #225 Raleigh United States of America 27612
- IPO Date
- Jun 25, 2002
- CIK
- 0001103021
- Website
- bdsi.com
- Similar Companies
- Business
- BioDelivery Sciences International, Inc. (BDSI) operates as a specialty pharmaceutical company that develops and commercializes innovative therapies for patients living with serious and debilitating chronic conditions, including chronic pain, opioid dependence, opioid-induced constipation, breakthrough cancer pain, and migraine, primarily in the United States and Canada. The company utilizes its proprietary patented BioErodible MucoAdhesive (BEMA) drug-delivery technology, a small erodible polymer film applied to the buccal mucosa (lining inside the cheek), alongside other delivery technologies, to offer products such as BELBUCA (buprenorphine buccal film, Schedule III) for chronic pain management; Symproic (naldemedine) for opioid-induced constipation; ELYXYB (celecoxib oral solution) for the acute treatment of migraine with or without aura in adults; BUNAVAIL (buprenorphine and naloxone buccal film) for opioid dependence; and ONSOLIS (fentanyl buccal soluble film) for breakthrough pain in cancer patients. BDSI targets prescribers and patients in the healthcare sectors of pain management, neurology, and addiction medicine. Founded in 1997 and headquartered in Raleigh, North Carolina, BDSI conducted its initial public offering in 2002 before becoming a wholly-owned subsidiary of Collegium Pharmaceutical, Inc. following its acquisition in March 2022 for approximately $604 million in an all-cash transaction valued at $5.60 per share. In the 1-2 years leading up to the acquisition, BDSI completed the acquisition of U.S. and Canadian rights to ELYXYB from Dr. Reddy’s Laboratories in September 2021, enabling expansion into the neurology market with a planned commercial launch in early 2022 and patent protection through 2036; reported strong financial performance including Q3 2021 net revenues of $41.1 million (up 4% year-over-year) and full-year 2021 guidance of $162-167 million; and successfully defended key patents for BELBUCA, securing exclusivity until 2032. Post-acquisition, BDSI's products, including BELBUCA and Symproic, have been integrated into Collegium's portfolio of abuse-deterrent and controlled-release pharmaceuticals, with no significant standalone operational changes, new product launches, partnerships, funding rounds, or reorganizations reported for BDSI since March 2022. The BDSIW ticker represents warrants associated with BDSI's historical capitalization structure.